tbuckley/cabot-search huggingface dataset:
OP0170 Low Income Is Associated with Lower Functional Capacity and Higher Disease Burden in RA Patients Younger than 65: Table 1.
Authors: J. Callhoff, K. Albrecht, F. Hoffmann, A. Luque Ramos, A. Zink
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Low socioeconomic status is known to be a risk factor for unfavourable outcomes in rheumatoid arthritis (RA). <h3>Objectives</h3> The aim of this analysis was to assess the influence of low income on functional capacity and disease burden. <h3>Methods</h3> Patients with a diagnosis of RA (ICD-10 codes M05 or M06) in at least two quarters in 2013 from a large statutory health insurance in Germany (Barmer GEK) were randomly selected, stratified by age (18–49/50–64/65–80), sex and diagnosis (M05/M06). They were contacted by mail and asked to complete a questionnaire regarding self-reported diagnosis (for validation of claims diagnosis), sociodemographics, health behaviour, impact of RA on employment, the RA Impact of Disease questionnaire (RAID, 0: no impact, 10: highest impact) and the physical function questionnaire FFbH (0: total impairment- 100: full function). General linear models were used to assess the association of income and other sociodemographic factors with the FFbH and the RAID. <h3>Results</h3> Of the 6,195 patients who were contacted, a total of 3,212 completed the questionnaire and 2,585 (80%) reported to have RA. Among those, 2,406 patients reported their household income. 31% of these had a low (&lt;1,500 Euro), 54% a medium (1,500–3,200 Euro) and 15% a high (&gt;3,200 Euro) household income. Patients with a low income had a mean FFbH of 67 (standard deviation 23) and a mean RAID of 4.8 (2.3), patients with a medium income had a mean FFbH of 74 (22) and a RAID of 4.1 (2.3) and those with a high income had a mean FFbH of 83 (18) and a RAID of 3.5 (2.3). In patients &lt;65 years (n=1353), FFbH and RAID differed between patients with low and medium/high income (table 1) while education and lifestyle (smoking, being stressed) were not associated, insufficient exercise was only associated with FFbH. This analysis was controlled for the following work-related parameters that were strongly associated with functional capacity and disease burden: being less efficient at work, being on sick leave &gt;6 weeks, having applied for disability pension and fear of not being able to work until retirement. <h3>Conclusions</h3> In patients with RA aged below 65, low income was strongly associated with higher disease burden und poorer function. The effect of income on function and overall disease burden remained after controlling for factors like considering or applying for disability pension, presenteism and absenteism. <h3>Acknowledgement</h3> This study was funded by the German Federal Ministry of Education and Research (01EC1405). <h3>Disclosure of Interest</h3> None declared
Changes in Expert Recommendations and Global Practice Patterns from 2012-2015: Results from an Annually Updated Online Decision Aid for Multiple Myeloma (MM)
Authors: Timothy A Quill, Shaji K Kumar, Suzanne Lentzsch, Sagar Lonial, G. David Roodman, Erik D. Brady, Jim Mortimer, Kevin L Obholz, Kenneth C Anderson
Journal: Blood (2015)
Impact of Comorbidities and Prospective Functional Geriatric Assessment Tools (CF-GA) As an Aide to Understand Outcome, Therapy Tolerance, Side Effects and Clinical Trial Eligibility in Multiple Myeloma (MM) Patients (pts)
Authors: Alexander Zober, Mandy Möller, Sandra-Maria Dold, Gabriele Ihorst, Stefanie Hieke, Jochen Knaus, Milena Pantic, Barbara Deschler-Baier, Stefan Knop, Hermann Einsele, Christian Langer, Lars-Olof Muegge, Wolfram Poenisch, Justus Duyster, Martin Schumacher, Ralph M. Waesch, Monika Engelhardt
Journal: Blood (2015)
Interterleukin-6 (IL-6) Produced by Monocyte Activation Reduces Dendritic Cell (DC) Differentiation in Patients with Multiple Myeloma (MM) and Malignant Lymphoma (ML): Role of CNTO 328, an Anti-IL-6 Monoclonal Antibody (Mab) and Possible Clinical Applications.
Authors: Jean-Francois Rossi, Anne-Marie Conge, Catherine Barjot, Mohamed H. Zaki, Marian T. Nakada, Robert Corringham, Bernard Klein
Journal: Blood (2004)
Transcription Factor Bach1 and Bach2 Control Common Myeloid Progenitor Cell Differentiation Under Infectious Stimuli
Authors: Hiroki Kato, Ari Itoh-Nakadai, Risa Ebina-Shibuya, Masahiro Kobayashi, Mitsuyo Matsumoto, Akihiko Muto, Tohru Fujiwara, Hideo Harigae, Kazuhiko Igarashi
Journal: Blood (2015)
Non Myeloablative Transplant in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.
Authors: M.D. Caballero, R. Martino, M.V. Mateos, J. Briones, J. de la Serna, J.F. Tomas, R. Arranz, J.L. Diez, V. Rubio, Josep Maria Ribera, J.M. Moraleda, G. Sanz, A. Urbano, J. Sarrá, A. Sampol, J. Sierra
Journal: Blood (2004)
Health Care Utilization by Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.
Authors: Smita Bhatia, Andrea Carter, Liton Francisco, K. S. Baker, Stephen J. Forman, Marcia Grant, Leslie L. Robison, Daniel J. Weisdorf, James G. Gurney
Journal: Blood (2004)
Significance of Minimal Residual Disease in Patients with Chronic Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Iwona Solarska, Barbara Nasilowska-Adamska, Maria Bieniaszewska, Jan Maciej Zaucha, Piotr Rzepecki, Waldemar Sawicki, Malgorzata Calbecka, Ewa Lech-Maranda, Bozena Marianska, Krzysztof Warzocha
Journal: Blood (2009)
Clinical Use of Caspofungin in Immunocompromised Children: A Multicenter Survey.
Authors: Thomas Lehrnbecher, Andishe Attarbaschi, Friedhelm Schuster, Nadine Herzog, Lorenz Grigull, Michael Dworzak, Karin Beutel, Hans-Jürgen Laws, Andreas H. Groll
Journal: Blood (2004)
Early pregnancy vitamin D status and risk of preeclampsia
Authors: Hooman Mirzakhani, Augusto A. Litonjua, Thomas F. McElrath, George O’Connor, Aviva Lee-Parritz, Ronald Iverson, George Macones, Robert C. Strunk, Leonard B. Bacharier, Robert Zeiger, Bruce W. Hollis, Diane E. Handy, Amitabh Sharma, Nancy Laranjo, Vincent Carey, Weilliang Qiu, Marc Santolini, Shikang Liu, Divya Chhabra, Daniel A. Enquobahrie, Michelle A. Williams, Joseph Loscalzo, Scott T. Weiss
Journal: Journal of Clinical Investigation (2016)

Low vitamin D status in pregnancy was proposed as a risk factor of preeclampsia.We assessed the effect of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10-18 weeks), on the development of preeclampsia. The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia incidence at trial entry and in the third trimester (32-38 weeks) were studied. We also conducted a nested case-control study of 157 women to investigate peripheral blood vitamin D-associated gene expression profiles at 10 to 18 weeks in 47 participants who developed preeclampsia.Of 881 women randomized, outcome data were available for 816, with 67 (8.2%) developing preeclampsia. There was no significant difference between treatment (N = 408) or control (N = 408) groups in the incidence of preeclampsia (8.08% vs. 8.33%, respectively; relative risk: 0.97; 95% CI, 0.61-1.53). However, in a cohort analysis and after adjustment for confounders, a significant effect of sufficient vitamin D status (25OHD ≥30 ng/ml) was observed in both early and late pregnancy compared with insufficient levels (25OHD <30 ng/ml) (adjusted odds ratio, 0.28; 95% CI, 0.10-0.96). Differential expression of 348 vitamin D-associated genes (158 upregulated) was found in peripheral blood of women who developed preeclampsia (FDR <0.05 in the Vitamin D Antenatal Asthma Reduction Trial [VDAART]; P < 0.05 in a replication cohort). Functional enrichment and network analyses of this vitamin D-associated gene set suggests several highly functional modules related to systematic inflammatory and immune responses, including some nodes with a high degree of connectivity.Vitamin D supplementation initiated in weeks 10-18 of pregnancy did not reduce preeclampsia incidence in the intention-to-treat paradigm. However, vitamin D levels of 30 ng/ml or higher at trial entry and in late pregnancy were associated with a lower risk of preeclampsia. Differentially expressed vitamin D-associated transcriptomes implicated the emergence of an early pregnancy, distinctive immune response in women who went on to develop preeclampsia.ClinicalTrials.gov NCT00920621.Quebec Breast Cancer Foundation and Genome Canada Innovation Network. This trial was funded by the National Heart, Lung, and Blood Institute. For details see Acknowledgments.
The Lancet Countdown: tracking progress on health and climate change
Authors: Nick Watts, W Neil Adger, Sonja Ayeb-Karlsson, Yuqi Bai, Peter Byass, Diarmid Campbell-Lendrum, Tim Colbourn, Peter Cox, Michael Davies, Michael Depledge, Anneliese Depoux, Paula Dominguez-Salas, Paul Drummond, Paul Ekins, Antoine Flahault, Delia Grace, Hilary Graham, Andy Haines, Ian Hamilton, Anne Johnson, Ilan Kelman, Sari Kovats, Lu Liang, Melissa Lott, Robert Lowe, Yong Luo, Georgina Mace, Mark Maslin, Karyn Morrissey, Kris Murray, Tara Neville, Maria Nilsson, Tadj Oreszczyn, Christine Parthemore, David Pencheon, Elizabeth Robinson, Stefanie Schütte, Joy Shumake-Guillemot, Paolo Vineis, Paul Wilkinson, Nicola Wheeler, Bing Xu, Jun Yang, Yongyuan Yin, Chaoqing Yu, Peng Gong, Hugh Montgomery, Anthony Costello
Journal: The Lancet (2016)
Molecular Characterization of Human Multiple Myeloma Cell Lines by Genome-Wide Profiling Identifies Kinase Pathway Alterations.
Authors: Carolina Elosua, Purificacion Catalina, Brian A Walker, Nicholas J Dickens, Athanasia Avramidou, Luis Brito, Emma Davenport, Matthew W Jenner, David Gonzalez, Faith Davies, Gareth J Morgan, Paola E Leone
Journal: Blood (2008)
AB0152 Clustered Autoantibody Reactivity Profiles and Definition of Homogeneous Systemic Lupus Erythematosus (SLE) Patient Groups
Authors: P. Schulz-Knappe, P. Budde, H. Goehler, H.-D. Zucht, M. Schneider, S. Vordenbäumen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In SLE, early diagnosis, differentiation to other autoimmune diseases and prognostic stratification are still great challenges. Hence, SLE represents an enormous challenge for the clinical development of effective therapies. Detecting a broad set of SLE-associated autoantibodies might help to utilize overall reactivities, co-prevalence and similarities of autoantibody reactivities in SLE patients. Such measures are expected to generate homogeneous SLE-subgroups which may represent common underlying pathophysiologies with different response to medicines and hence orffer improved medical care options. <h3>Objectives</h3> Here, we describe the development of a multiplexed autoantibody assay incorporating over 40 known SLE-antigens plus novel human protein antigens derived from large scale autoantibody screening in SLE and other autoimmune diseases such as rheumatoid arthritis, systemic sclerosis and healthy controls, The resulting assay is intendedto comprehensively analyse 87 autoantibodies in SLE patients for disease subgroupd formation. <h3>Methods</h3> A Luminex bead-based autoantibody assay was designed by combining traditional with novel biomarkers. Antigens were selected to be used for a) the diagnosis and b) differential diagnosis of SLE, have previously been linked to c) disease activity, and d) specific organ involvement, are encoded by e) interferon type I response genes, and f) may have utility for patient subgrouping. Autoantibody reactivity against these antigens was tested in over 700 SLE, healthy controls (n=1000), and autoimmune disease samples (n=500). <h3>Results</h3> Based on the individual marker pattern, we defined an autoantibody reactivity score and four SLE patient clusters (C1-C4) including patients: C1: with a higher disease activity score, broad and homogeneous autoantibody reactivity; C2: with broad, but heterogeneous autoantibody reactivity; C3) who have few autoantibodies and C4) with unusual autoantibody pattern. <h3>Conclusions</h3> High content autoantibody profiling of SLE patients reveals relevant differences in autoantibody reactivities both in amount of total reactivity as well as towards autoantibody clusters indicating specific pathophysiologies. Although more studies are needed, our findings suggest that SLE patients can be stratified into distinct, homogenous subgroups. This might be useful in clinical studies to increase the probability of successful drug development. <h3>Disclosure of Interest</h3> P. Schulz-Knappe Employee of: Protagen AG, P. Budde Employee of: Protagen AG, H. Goehler Employee of: Protagen AG, H.-D. Zucht Employee of: Protagen AG, M. Schneider: None declared, S. Vordenbäumen: None declared
Obese Patients Have Improved Survival Following Autologous Hematopoietic Stem Cell Transplantation
Authors: Hien K. Duong, Anna Koo, Lisa Rybicki, Ed Copelan, Matt Kalaycio, Ronald Sobecks, Robert M Dean, Brian T. Hill, Sarah L. Ondrejka, Donna M Abounader, Brad Pohlman, Brian J. Bolwell
Journal: Blood (2012)
Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders
Authors: Pau Montesinos, David Martinez, Joaquin Martínez, Raimundo Garcia, Jaime Pérez de Oteyza, Pascual Fernandez, Josefina Serrano, Angeles Fernandez, Pilar Herrera, Arancha Alonso, Ataulfo Gonzalez, Concepcion Bethancourt, Esperanza Lavilla, Juan Antonio Vera, Begoña Navas, Gabriela Rodriguez, Juan Antonio Lopez, Santiago Jimenez, Adriana Simiele, Bernardo Gonzalez, Jose Angel Hernandez, Raul Cordoba, Consolación Rayón, Carmen Burgaleta, Jordi Sierra, Iñaki Troconiz, Ignacio Ortega, Andrew G. Bosanquet, Daniel Primo, Pilar Hernandez-Campo, Julian Gorrochategui, Jose L. Rojas, Teresa A. Bennett, Belen Liebana, Rocio Lopez, Joan Ballesteros, Federico Moscardo, Miguel Sanz
Journal: Blood (2013)
Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions
Authors: N.G. Maher, T.P. Blumetti, E.E. Gomes, H.M. Cheng, L. Satgunaseelan, S. Lo, G.G. Rezze, R.A. Scolyer, P. Guitera
Journal: British Journal of Dermatology (2016)

Amelanotic and hypomelanotic skin lesions can be difficult to diagnose clinically and dermoscopically.1-3 Evidence is emerging that optical coherence tomography (OCT) can detect superficial basal cell carcinoma (sBCC) with good sensitivity (79-95.7%) and specificity (75.3-96%).4 Given that sBCC is a common problem4, and that it may be treated noninvasively5, the potential benefits from using OCT as an adjunct to clinical diagnosis are high. However, if OCT is used without histopathological confirmation in this setting, there is a risk that more clinically aggressive malignant pathology, such as amelanotic /hypomelanotic melanoma (AHM), may be misdiagnosed and left to progress if it is inadequately treated. Indeed, this research was prompted after experiencing a clinical case where a lesion had typical clinical-dermoscopic and OCT features for sBCC, but histopathology revealed an amelanotic melanoma.

This article is protected by copyright. All rights reserved.
The Cyclin Interactor p26INCA1 Regulates the Hematopoietic Stem Cell Pool Via CDK Inhibition.
Authors: Nicole Baeumer, Sven Diederichs, Steffen Koschmieder, Boris V. Skryabin, Feng Zhang, Martin Stehling, Gabriele Koehler, Wolfgang E. Berdel, Hubert Serve, Carsten Mueller-Tidow
Journal: Blood (2007)
THU0381 The Incidence of Herpes Zoster Infection in Patients with Ankylosing Spondylitis: Analysis from Korean National Health Insurance Service–Cohort Sample Database: Table 1.
Authors: D.-H. Lim, S.M. Ahn, S. Hong, Y.-G. Kim, C.-K. Lee, B. Yoo, T.-H. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Herpes zoster (HZ) infection occurs more commonly in patients with underlying autoimmune disease, partially due to immunosuppressive treatment. However, little is known about the incidence of HZ in patients with ankylosing spondylitis (AS), especially who were treated with conventional disease modifying anti-rheumatic drugs (cDMARDs) or TNF inhibitors. <h3>Objectives</h3> The aims of our study were to investigate the incidence of HZ in AS patients and to determine whether use of cDMARDs or TNF inhibitors could increase the risk of HZ infection in AS patients. <h3>Methods</h3> We used database of the Korean National Health Insurance Service–Cohort Sample (1,025,340 individuals) from 2002 to 2013, which was age-, gender-, district- and income stratified random sample. We evaluated HZ incidence among three groups (non-DMARD users, cDMARDs [sulfasalazine, methotrexate] users and TNF inhibitor users) based on drug exposure episodes. Cox proportional hazard analysis was performed to investigate the association between treatment group and HZ infection. <h3>Results</h3> Among 1,079 patients with AS, we identified 54 HZ infections. Crude incidence rates were 11.0 per 1000 patient-years (95% CI, 8.2–14.3) in all AS patients; 9.1 (95% CI, 6.2–12.8) in non-DMARD users, 16.7 (95% CI, 9.1–28.0) in cDMARDs users and 14.1 (95% CI, 6.1–27.8) in TNF inhibitor users, respectively. Adjusted hazard ratio (HR) of HZ infection was higher in cDMARDs users and TNF inhibitor users than in non-DMARD users (Table). In subgroup analysis, TNF inhibitor increased the risk of HZ infection more significantly in female (adjusted HR =8.01; 95% CI, 1.97–32.54) and patients older than 50-yr (adjusted HR =7.29; 95% CI, 1.88–28.21), but not in patients exposed to baseline corticosteroid (95% CI, 0.53–32.84) compared to non-DMARD users. <h3>Conclusions</h3> The incidence of HZ in AS patients was 11.0 per 1000 patient-years which is similar to the previously reported incidence in general Korean population. cDMARDs or TNF inhibitors increased the risk of HZ infection in AS patients, especially in female and older patients, which can be considered as target of HZ vaccination in AS population. <h3>Disclosure of Interest</h3> None declared
Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data
Authors: Giuseppe Saglio, Hagop M. Kantarjian, Neil Shah, Elias J. Jabbour, Alfonso Quintas-Cardama, Juan Luis Steegmann, Concepción Boqué, Charles Chuah, Carolina Pavlovsky, Jiří Mayer, Jon Ukropec, Mark Wildgust, Andreas Hochhaus
Journal: Blood (2012)
Social identification is generally a prerequisite for group success and does not preclude intragroup differentiation
Authors: S. Alexander Haslam, Naomi Ellemers
Journal: Behavioral and Brain Sciences (2016)

On the basis of research in the social identity tradition, we contend (a) that identification and differentiation are not mutually exclusive, (b) that a sequence in which identification gives way to differentiation is not necessarily associated with superior organizational outcomes, and
GvATLL Effect in the Relapse and Progression Cases After Hematopoietic Stem Cell Transplantation (HSCT) for Adult T-Cell Leukemia/Lymphoma (ATLL).
Authors: Nobuaki Nakano, Ayumu Kubota, Mayumi Tokunaga, Masahito Tokunaga, Shogo Takeuchi, Yosifusa Takatsuka, Atae Utsunomiya
Journal: Blood (2009)
A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma
Authors: Emma C. Scott, Dan T. Vogl, Shara Reasor-Heard, Kevin Floyd, Eva Medvedova, Stephen E. Spurgeon, Miranda Gordon, Anne Kratz, Matthew B. Siegel, Marc Loriaux, Phoebe Trubowitz, Stephen D Smith, Selina Qiuying Liu, Ranjana Arora, Edward A. Stadtmauer, Ravi K. Amaravadi, Richard T. Maziarz
Journal: Blood (2014)
O105 : Comparison of short-term and long-term outcomes after DCD and DBD donor liver transplantation
Authors: M. Cortes, S. Khorsandi, D. Chasiotis, R. Patcha, B. Amir Sayed, M. Tedeschi, Y. Puri, B. Reyes, M. Diaz, G. Rompianesi, M. Heneghan, J. O’Grady, H. Vilca-Melendez, K. Menon, A. Prachalias, P. Srinivasan, M. Rela, N. Heaton, W. Jassem
Journal: Journal of Hepatology (2015)
Symptoms that may suggest pancreatic cancer are identified
Authors: Jacqui Wise
Journal: BMJ (2016)

GPs should be alert to the possibility of pancreatic cancer in patients with symptoms such as jaundice, fatigue, change in bowel habit, weight loss, or decreased appetite, particularly in those with diabetes or mental health problems, say researchers in the journal Lancet Gastroenterology and Hepatology .1

Their study, the first to look at symptoms in people before they get pancreatic cancer diagnosed, found no initial warning signs that could help GPs identify pancreatic cancer, but they noted a range of subsequent symptoms that help predict this diagnosis.

Survival from pancreatic cancer is very poor, as less than 5% of patients survive more than …
Prognostic Value of Early 18fluorodeoxyglucose PET Scan in Patients with Diffuse Large B Cell Lymphoma Treated with Rituximab Plus CHOP or High-Dose CHOP.
Authors: Jehan Dupuis, Emmanuel Itti, Christophe Fruchart, Stéphane Bardet, Alain Rahmouni, Jean-Pierre Vilque, Chieh Lin, Karim Belhadj, Taoufik El Gnaoui, Frédérique Kuhnowski, Michel Meignan, Corinne Haioun
Journal: Blood (2008)
Impact of V617F JAK2 Mutation on Monocyte Tissue Factor and Procoagulant Activity in Patients with Essential Thrombocythemia(ET) or Polycythemia VERA (PV)
Authors: Anna Falanga, Alfonso Vignoli, Marina Marchetti, Laura Russo, Marina Panova-Noeva, Donatella Balducci, Silvia Salmoiraghi, Tiziano Barbui, Hugo ten Cate, Alessandro Rambaldi
Journal: Blood (2008)
WT1-Specific CD8+ T Lymphocytes May Participate in the Elimination of Acute Lymphoblastic Leukemia Following Allogeneic Stem Cell Transplantation.
Authors: Katayoun Rezvani, Agnes Yong, Stephan Mielke, Bipin N. Savani, David A. Price, Emma Gostick, Daniel C. Douek, A. John Barrett
Journal: Blood (2006)